Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis

Huang, Mingjian; Zhao, Jingyu; Huang, Yan; Dai, Liming; Zhang, Xiaoling

doi:10.1016/j.jot.2017.06.005

Cited by 18 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a moderate correlation was found between urinary CTX-II levels and KL grades (r = 0.405, p < 0.001) and the multiple linear regression analysis demonstrated that urinary CTX-II was independently associated with KL grades, suggesting that urinary CTX-II levels are increased in patients with an increased OA severity. Recent meta-analysis also revealed that urinary CTX-II levels were consistently increased in patients with severe knee OA on radiographic evaluation compared to that in those with mild knee OA [14,15,24]. Therefore, urinary CTX-II could be a useful tool for monitoring OA disease progression and treatment outcomes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Can urinary CTX-II be a biomarker for knee osteoarthritis?

et al. 2020

View full text Add to dashboard Cite

Background: Early diagnosis of knee osteoarthritis (OA) remains a diagnostic challenge. Urinary C-terminal crosslinked telopeptide of type II collagen (urinary CTX-II) is one of the potential OA biomarkers. However, conclusive evidence regarding the use of this biomarker as a tool for early diagnosis is still lacking. The purposes of this study were to compare urinary CTX-II levels in patients with knee OA and in healthy controls, to evaluate the correlation between urinary CTX-II levels, radiographic severity of OA, and patient-reported outcomes and to evaluate the effect of age and gender on urinary CTX-II levels in the Asian populations. Methods: Two groups were studied. The OA group included 78 patients with knee OA aged > 40 years who met the diagnostic criteria for knee OA described by the American College of Rheumatology (ACR). The control group consisted of 51 healthy participants age > 40 years without clinical or radiographic evidence of knee OA. Bilateral knee radiographs were taken and classified according to the Kellgren and Lawrence (KL) grading system. Urinary CTX-II was measured using a competitive ELISA test and Western Ontario and Mcmaster Universities Arthritis Index (WOMAC) was also recorded in all participants. Results: Urinary CTX-II was significantly higher in the OA group than in the control group (p < 0.001). The severe knee OA group (KL grade 3 and 4) had higher urinary CTX-II levels than mild knee OA group (KL grade 2) but the difference did not reach statistical significance (p = 0.2). There was a moderate correlation between urinary CTX-II levels and KL grades (r = 0.405, p < 0.001) and a weak correlation between urinary CTX-II levels and WOMAC index scores (r = 0.367, p < 0.001). Multiple regression analysis showed that urinary CTX-II was independently associated with KL grades. Whereas age, gender, and WOMAC index had no statistically significant influence on the urinary CTX-II levels.Conclusions: Patients with knee OA had higher urinary CTX-II levels than healthy controls. Moreover, levels of urinary CTX-II were independently correlated with radiographic severity of knee OA. Age, gender, and patient-reported outcomes exerted no effect on the urinary CTX-II levels.Level of evidence: Diagnostic Level III.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Additionally, recent meta-analyses showed the potential of using urinary CTX-II levels to distinguish between patients with knee OA from healthy controls. However, this diagnostic feature is not upheld in Asian populations, probably due to the small number of studies that were conducted in Asia [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Can urinary CTX-II be a biomarker for knee osteoarthritis?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Subchondral bone provides structural support and shock absorber for superficial articular cartilage and undergoes dynamic balance between modeling and remodeling in response to mechanical stress . The process of bone remodeling is regulated by osteoclast and osteoblast activity, and abnormal remodeling is believed to trigger the onset of OA . However, whether the degeneration in subchondral bone is the principal factor for LFJ OA and the source of LBP needs to be further explored.…”

mentioning

confidence: 99%

“…9,10 The process of bone remodeling is regulated by osteoclast and osteoblast activity, and abnormal remodeling is believed to trigger the onset of OA. 11,12 However, whether the degeneration in subchondral bone is the principal factor for LFJ OA and the source of LBP needs to be further explored. Furthermore, the specific mechanism involved in this disease progression and potential therapy remains to be further evaluated.…”

mentioning

confidence: 99%

BMSCs‐Derived Exosomes Ameliorate Pain Via Abrogation of Aberrant Nerve Invasion in Subchondral Bone in Lumbar Facet Joint Osteoarthritis

Ding

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Lumbar facet joint osteoarthritis (LFJ OA) is regarded as one of the common causes of low back pain (LBP). The pathogenesis and underlying mechanism of this disease are largely unknown, there is still no effective disease‐modifying therapy. This study aims to investigate the efficacy of exosomes derived from bone marrow mesenchymal stem cells (BMSCs) on the pathogenesis and behavioral signs of LBP in the LFJ OA mouse model. The pathogenetic change in cartilage and aberrant nerve invasion in the subchondral bone of LFJ in a mouse model after treatment with BMSC‐exosomes was evaluated. BMSC‐exosomes could relieve pain via abrogation of aberrant CGRP‐positive nerve and abnormal H‐type vessel formation in the subchondral bone of LFJ. Moreover, BMSC‐exosomes attenuated cartilage degeneration and inhibited tartrate‐resistant acid phosphatase expression and RANKL‐RANK‐TRAF6 signaling activation to facilitate subchondral bone remodeling. These results indicated that BMSC‐exosomes could relive behavioral signs of LBP and pathological processes in LFJ OA. BMSC‐exosomes have a prominent protective effect and might be a potential therapeutic option for the treatment of LFJ OA causing LBP. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:670–679, 2020

show abstract

“…All statistical analyses were performed using the Review Manager (RevMan) software [ 35 ]. Publication bias was assessed by Begg's test and Egger's test with the STATA software version 12.0 [ 36 ].…”

Section: Methodsmentioning

confidence: 99%

Pulmonary Rehabilitation Can Improve the Functional Capacity and Quality of Life for Pneumoconiosis Patients: A Systematic Review and Meta-Analysis

Zhao

Xie

Wang³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

This study evaluated the efficacy and safety of pulmonary rehabilitation (PR) for pneumoconiosis. We systematically searched PubMed, Embase, The Cochrane Library, Web of Science, SinoMed, CNKI, VIP databases and Wanfang Data from their inception to June 1, 2019. A systematic review and meta-analysis of randomized controlled trials (RCTs) of PR for pneumoconiosis was conducted and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two reviewers independently screened literature, extracted data, and assessed bias risk. All statistical analyses were performed using the RevMan software. Sixteen RCTs with 1307 subjects were ultimately included for analysis. Compared with routine treatment, PR was able to improve the 6-minute walking distance (mean difference (MD) 69.10, 95% confidence interval (CI) 61.95–76.25); the 36-Item Short Form Health Survey total score (MD 17.60, 95% CI 13.59–21.61); physical function score (MD 15.45, 95% CI 3.20–27.69); role physical score (MD 17.87, 95% CI 12.06–23.69); body pain score (MD 14.34, 95% CI 10.33–18.36); general health score (MD 20.86, 95% CI 16.87–24.84); vitality score (MD 11.66, 95% CI 0.18–23.13); social function score (MD 9.67, 95% CI 1.27–18.08); mental health score (MD 20.60, 95% CI 13.61–27.59); forced vital capacity (FVC) (MD 0.20, 95% CI 0.12–0.29); forced expiratory volume in 1 s (FEV1) (MD 0.23, 95% CI 0.09–0.38); FEV1% (MD 5.19, 95% CI 1.48–8.90); maximal voluntary ventilation (MD 4.47, 95% CI 1.14–7.81); reduction in the St. George’s Respiratory Questionnaire score (MD -9.60, 95% CI -16.40 to -2.80); and the modified Medical Research Council Scale score. Furthermore, PR did not increase the FEV1/FVC (MD 3.61, 95% CI -3.43 to 10.65), nor the emotional score (MD 6.18, 95% CI -23.01 to 35.38) compared with the control. We found no reports of adverse events associated with PR. Thus, to some extent, PR can improve functional capacity and quality of life in patients with pneumoconiosis. However, these results should be interpreted with caution because of high heterogeneity. This trial is registered with registration number CRD42018095266.

show abstract

Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis

Cited by 18 publications

References 24 publications

Can urinary CTX-II be a biomarker for knee osteoarthritis?

Can urinary CTX-II be a biomarker for knee osteoarthritis?

BMSCs‐Derived Exosomes Ameliorate Pain Via Abrogation of Aberrant Nerve Invasion in Subchondral Bone in Lumbar Facet Joint Osteoarthritis

Pulmonary Rehabilitation Can Improve the Functional Capacity and Quality of Life for Pneumoconiosis Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About